Short Interest in Singular Genomics Systems, Inc. (NASDAQ:OMIC) Drops By 18.9%

Singular Genomics Systems, Inc. (NASDAQ:OMIC - Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 71,200 shares, a decrease of 18.9% from the October 15th total of 87,800 shares. Currently, 4.8% of the shares of the stock are sold short. Based on an average daily volume of 105,000 shares, the days-to-cover ratio is currently 0.7 days.

Singular Genomics Systems Price Performance

Shares of Singular Genomics Systems stock traded down $0.85 during trading on Friday, hitting $21.90. The stock had a trading volume of 29,598 shares, compared to its average volume of 34,549. The firm has a market cap of $55.01 million, a price-to-earnings ratio of -0.62 and a beta of 1.51. Singular Genomics Systems has a 12 month low of $5.34 and a 12 month high of $23.41. The business's 50-day moving average is $15.32 and its 200 day moving average is $11.33. The company has a current ratio of 7.37, a quick ratio of 8.04 and a debt-to-equity ratio of 0.04.

Singular Genomics Systems (NASDAQ:OMIC - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($6.72) earnings per share for the quarter, topping the consensus estimate of ($8.05) by $1.33. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.74 million. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 57.87%.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.